Matritech, Inc. - MZT- Profile

Matritech, Inc.. The Group's principal activity is to develop, produce and distribute products for the diagnosis and potential treatment of cancer. The products are based on proprietary nuclear matrix protein technology. The Group has developed minimally invasive cancer diagnostic tests for bladder and colon cancer, cervical cancer, breast cancer and prostrate cancer, using proprietary technology and expertise. The Group has NMP22(R), NMP179(R), BladderChek(R) and Matritech(R) registered trademarks and NMP35tm, NMP48tm and NMP66tm are trademarks. The major customers of the Group include Institut Fur Klinische and Fisher. The Group operates in the United States, Japan, Europe and in other countries. Develops, manufactures and markets innovative cancer diagnostic products based on proprietary nuclear matrix protein technology